NO20053846L - Fremgangsmate for a modifisere legemiddel-krystalldannelse - Google Patents

Fremgangsmate for a modifisere legemiddel-krystalldannelse

Info

Publication number
NO20053846L
NO20053846L NO20053846A NO20053846A NO20053846L NO 20053846 L NO20053846 L NO 20053846L NO 20053846 A NO20053846 A NO 20053846A NO 20053846 A NO20053846 A NO 20053846A NO 20053846 L NO20053846 L NO 20053846L
Authority
NO
Norway
Prior art keywords
crystal formation
drug crystal
modifying drug
modifying
crystals
Prior art date
Application number
NO20053846A
Other languages
English (en)
Inventor
Sabine Pfeffer
Dierk Wieckhusen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9951448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20053846(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20053846L publication Critical patent/NO20053846L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Det er beskrevet en fremgangsmåte for å modifisere krystalltilstanden av aciculære legemiddelstoffer, krystaller oppnådd ved en slik fremgangsmåte og spesielle krystallformer eller modifikasjoner av mycofenolsyre eller mycofenolatnatrium, så vel som farmasøytiske preparater omfattende krystallene, fremgangsmåter for behandling og anvendelse derav.
NO20053846A 2003-01-20 2005-08-16 Fremgangsmate for a modifisere legemiddel-krystalldannelse NO20053846L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0301259.8A GB0301259D0 (en) 2003-01-20 2003-01-20 Organic compounds
PCT/EP2004/000354 WO2004064806A2 (en) 2003-01-20 2004-01-19 Process for modifying drug crystal formation

Publications (1)

Publication Number Publication Date
NO20053846L true NO20053846L (no) 2005-08-16

Family

ID=9951448

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053846A NO20053846L (no) 2003-01-20 2005-08-16 Fremgangsmate for a modifisere legemiddel-krystalldannelse

Country Status (31)

Country Link
US (3) US20060122265A1 (no)
EP (2) EP2308471A1 (no)
JP (1) JP4549976B2 (no)
KR (5) KR100855149B1 (no)
CN (2) CN101333201A (no)
AR (2) AR043343A1 (no)
AT (1) ATE546132T1 (no)
AU (1) AU2004206731B2 (no)
BR (1) BRPI0406827A (no)
CA (2) CA2509796C (no)
CL (1) CL2004000073A1 (no)
CO (1) CO5580738A2 (no)
CY (1) CY1112772T1 (no)
DK (1) DK1592401T3 (no)
EC (1) ECSP055918A (no)
ES (1) ES2382035T3 (no)
GB (1) GB0301259D0 (no)
IL (1) IL169484A (no)
MX (1) MXPA05007691A (no)
MY (1) MY148297A (no)
NO (1) NO20053846L (no)
NZ (1) NZ541073A (no)
PE (2) PE20040826A1 (no)
PL (2) PL376525A1 (no)
PT (1) PT1592401E (no)
RU (1) RU2388757C2 (no)
SG (1) SG155046A1 (no)
SI (1) SI1592401T1 (no)
TW (1) TWI325785B (no)
WO (1) WO2004064806A2 (no)
ZA (1) ZA200504442B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
MXPA06005659A (es) 2004-04-26 2007-04-10 Teva Gyogyszergyar Zartkoruen Proceso para preparacion de acido micofenolico y derivados de ester del mismo.
EP1740563A2 (en) 2004-04-27 2007-01-10 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Mycophenolate mofetil impurity
US7439373B2 (en) 2004-07-20 2008-10-21 TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság Crystalline mycophenolate sodium
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
US20080176937A1 (en) * 2007-01-23 2008-07-24 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
ES2391132T3 (es) * 2008-10-09 2012-11-21 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Uso de disolventes orgánicos en la granulación húmeda de moxifloxacino
CN101756958B (zh) * 2008-11-10 2011-07-20 鲁南制药集团股份有限公司 一种治疗关节炎的药物组合物及其制备方法
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
EP2451797B1 (en) * 2009-07-10 2013-04-03 Janssen Pharmaceutica, N.V. CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE
EA201270544A1 (ru) * 2009-10-13 2012-09-28 Тева Фармасьютикал Индастриз Лтд. Композиции с отсроченным высвобождением
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
SG10201506114UA (en) 2010-05-11 2015-09-29 Janssen Pharmaceutica Nv Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
CN103880800A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103880799A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
EP2697218B1 (en) 2011-04-13 2016-05-25 Janssen Pharmaceutica NV Process for the preparation of compounds useful as inhibitors of sglt2
TWI582078B (zh) * 2013-01-23 2017-05-11 北京貝美拓新藥研發有限公司 抑制脯氨酸羥化酶活性的化合物的晶型及其應用
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
HUE049895T2 (hu) * 2015-12-21 2020-11-30 Janssen Pharmaceutica Nv Kristályosítási eljárás kanagliflozin hemihidrát kristályok elõállítására
MX2019009843A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
CN108727318A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 麦考酚酸的晶型物
CN108727317A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 一种麦考酚酸的晶型物
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CN110922371B (zh) * 2019-12-27 2020-08-11 广东蓝宝制药有限公司 一种m2晶型麦考酚钠的制备方法
CN120208923A (zh) 2020-05-18 2025-06-27 诺华股份有限公司 Lnp023的结晶形式
KR20250013155A (ko) * 2022-05-31 2025-01-31 혼슈우 카가쿠고교 가부시키가이샤 4,4'－비스(1,1－비스(4－히드록시－3－메틸페닐)에틸)비페닐의 결정 및 그의 제조방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US158835A (en) * 1875-01-19 Improvement in mortising-tools
GB935432A (en) * 1958-05-29 1963-08-28 Secr Aviation Improvements in the manufacture of crystalline substances
US3187039A (en) * 1962-10-19 1965-06-01 Commercial Solvents Corp Method for changing the crystal habit of monosodium glutamate
US3183263A (en) * 1962-10-19 1965-05-11 Commercial Solvents Corp Method for changing the crystal habit of mono-sodium glutamate
US3352906A (en) * 1963-02-04 1967-11-14 Charles R Parkerson Habit modification and preparation of single crystal triglycine sulfate
GB1157100A (en) * 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
GB1157099A (en) * 1966-09-27 1969-07-02 Ici Ltd Fermentation Process
US3770390A (en) * 1971-02-26 1973-11-06 Dow Chemical Co Crystal habit modification of inorganic salts using polymeric sulfonates or sulfates
US4259239A (en) * 1980-04-21 1981-03-31 Allied Chemical Corporation Resolution of enantiomeric complexes of nickelous chloride and alpha-aminocaprolactam
IL60254A (en) 1980-06-08 1983-11-30 Yeda Res & Dev Resolution of amino acids
JPS5875194A (ja) * 1981-10-30 1983-05-06 株式会社日立製作所 マトリクス表示装置及び駆動方法
JPS59232916A (ja) * 1983-06-16 1984-12-27 Shiraishi Chuo Kenkyusho:Kk 針柱状炭酸カルシウム結束体、その製造法及び該結束体を含有する感熱紙用塗被組成物
IL77031A (en) 1985-11-12 1995-12-08 Yeda Res & Dev Kinetic resolution of racemic mixtures by polymer-bound crystallization inhibitors
JPH0745359B2 (ja) 1987-12-25 1995-05-17 東レ株式会社 有機化合物結晶の製造方法
EP0582452B1 (en) * 1992-08-04 1998-10-14 Toda Kogyo Corp. Granulated particles for magnetic particles for magnetic recording and process for producing the same
JP3411038B2 (ja) 1993-09-15 2003-05-26 シンテックス（ユー・エス・エイ）・インコーポレイテッド ミコフェノール酸モフェチルの結晶質無水物およびその静注用製剤
JPH09209297A (ja) * 1996-01-26 1997-08-12 Nippon Paper Ind Co Ltd 艶消し軽量塗工紙及びその製造方法
KR100491274B1 (ko) * 1996-04-12 2005-09-05 노파르티스 아게 미코페놀레이트의장용코팅된약제조성물
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
FR2780403B3 (fr) * 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP1592401A2 (en) 2005-11-09
MXPA05007691A (es) 2005-09-30
PE20040826A1 (es) 2004-12-23
SI1592401T1 (sl) 2012-05-31
IL169484A (en) 2016-03-31
PL393385A1 (pl) 2011-03-14
PE20110276A1 (es) 2011-05-27
AU2004206731A1 (en) 2004-08-05
US8124795B2 (en) 2012-02-28
ES2382035T3 (es) 2012-06-04
AU2004206731A8 (en) 2004-08-05
JP2006515016A (ja) 2006-05-18
AR043343A1 (es) 2005-07-27
JP4549976B2 (ja) 2010-09-22
KR20090115821A (ko) 2009-11-06
GB0301259D0 (en) 2003-02-19
DK1592401T3 (da) 2012-05-21
KR20050096940A (ko) 2005-10-06
US20060122265A1 (en) 2006-06-08
SG155046A1 (en) 2009-09-30
KR20070087181A (ko) 2007-08-27
CN1738605A (zh) 2006-02-22
PL376525A1 (pl) 2006-01-09
CL2004000073A1 (es) 2005-01-14
ATE546132T1 (de) 2012-03-15
ZA200504442B (en) 2006-02-22
EP1592401B1 (en) 2012-02-22
BRPI0406827A (pt) 2005-12-27
KR20090115898A (ko) 2009-11-09
MY148297A (en) 2013-03-29
WO2004064806A3 (en) 2004-10-28
CA2509796C (en) 2010-09-14
WO2004064806A2 (en) 2004-08-05
CO5580738A2 (es) 2005-11-30
RU2388757C2 (ru) 2010-05-10
KR101129105B1 (ko) 2012-04-12
IL169484A0 (en) 2007-07-04
PT1592401E (pt) 2012-05-10
ECSP055918A (es) 2005-11-22
US8008511B2 (en) 2011-08-30
HK1084874A1 (en) 2006-08-11
CA2509796A1 (en) 2004-08-05
AU2004206731B2 (en) 2008-03-20
PL213192B1 (pl) 2013-01-31
KR20100120321A (ko) 2010-11-15
CN100595199C (zh) 2010-03-24
KR100855149B1 (ko) 2008-08-28
CY1112772T1 (el) 2016-02-10
AR103711A2 (es) 2017-05-31
CN101333201A (zh) 2008-12-31
US20110288313A1 (en) 2011-11-24
US20090209639A1 (en) 2009-08-20
EP2308471A1 (en) 2011-04-13
RU2005126328A (ru) 2006-07-27
NZ541073A (en) 2008-12-24
CA2706900A1 (en) 2004-08-05
TWI325785B (en) 2010-06-11
TW200505505A (en) 2005-02-16

Similar Documents

Publication Publication Date Title
NO20053846L (no) Fremgangsmate for a modifisere legemiddel-krystalldannelse
NO20074012L (no) 1-tio-D-glucitolderivater
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
BRPI0315296B8 (pt) derivados do ciclohexanol espirocíclicos, medicamento incluindo pelo menos um derivado do ciclohexano espirocíclico e uso de um derivado do ciclohexano espirocíclico
NO950774L (no) Fremgangsmåte for inhibering av bentap og nedsettelse av serumkolesterol
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
NO20074390L (no) Forsterket bimatoprost oye-opplosning
BRPI0412997A (pt) derivados de dióxido de tiazol-benzoisotiazol substituìdos, método para produzir os mesmos e seu uso
NO20032734D0 (no) Nye 1,2-difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder nevnte forbindelser og anvendelse avdisse for behandling av sykdommer fra lipidstoffskiftet
NO20063382L (no) Nye kinolinderivater
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
NO20076638L (no) Nye 8-sulfonylamino-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptoren
NO20065904L (no) Terapeutiske forbindelser
NO20065926L (no) Substituerte oksazolbenzoisotiazoldioksidderivater samt fremgangsmate for fremstilling og anvendelse derav
NO20053467L (no) Fremgangsmate ved biotransformasjon av kolkionforbindelser til de tilsvarende 3-glykosyl-derivater
NO20050569L (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
NO20076405L (no) Anvendelse av 24-nor-UDCA
NO20063576L (no) 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes
NO20072668L (no) Ny kombinasjon
NO20062450L (no) Analgesiske suspensjoner med kontrollert frigivelse
NO20073772L (no) Preparater som omfatter et epotilon, og fremstillingsfremgangsmate
NO20060718L (no) Substituerte tiofoner og deres anvendelse
ATE438617T1 (de) Substituierte cyclohexyl-1,4-diamin-derivate
NO20074661L (no) Anvendelse av en forbindelse
NO20065835L (no) Medikamenter som inneholder N-sulfamoyl-N'-arylpiperaziner for profylakse eller behandling av overvekt og beslektede tilstander

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application